Heron Therapeutics Inc. (HTRX) Is Surging On Phase 3 Study Results

Heron Therapeutics Inc. (HRTX) announced Monday morning that its Phase 3 studies of HTX-011 in subjects undergoing bunionectomy and hernia repair achieved all primary and key secondary endpoints.

from RTT - Hot Stocks http://ift.tt/2GEWjKZ
via IFTTT